ROIV · Insider Trading
Roivant Sciences Ltd. Common Shares
Every open-market purchase and sale reported by ROIV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Frank Torti | President and Vant Chair | F | +40,309 | +$1.47M |
| 2026-10-02 | Mayukh Sukhatme | President & CIO | F | −46,879 | −$1.71M |
| 2026-10-02 | Matthew Gline | CEO | F | −76,171 | −$2.79M |
| 2026-10-02 | Eric Venker | President & Immunovant CEO | MIXED | — | −$6.55M |
| 2026-09-22 | Richard Pulik | CFO | F | −2,129 | −$84.67K |
| 2026-09-22 | Jennifer Humes | Chief Accounting Officer | F | −3,880 | −$154.31K |
| 2026-09-18 | Meghan Fitzgerald | Director | A | +5,054 | — |
| 2026-09-18 | Daniel Allen Gold | Director | A | +5,054 | — |
| 2026-09-18 | James C Momtazee | Director | A | +5,054 | — |
| 2026-09-18 | Ilan Oren | Director | A | +5,054 | — |
| 2026-09-18 | Keith S Manchester | Director | A | +5,054 | — |
| 2026-09-18 | Epperly Melissa B, | Director | A | +5,054 | — |
| 2026-09-17 | Meghan Fitzgerald | Director | Sell | −5,112 | −$203.15K |
| 2026-09-17 | Epperly Melissa B, | Director | Sell | −4,938 | −$196.23K |
| 2026-09-14 | Meghan Fitzgerald | Director | F | −1,743 | −$71.36K |
| 2026-09-14 | James C Momtazee | Director | F | −2,905 | −$118.93K |
| 2026-09-14 | Ilan Oren | Director | F | −2,378 | −$97.36K |
| 2026-09-14 | Daniel Allen Gold | Director | F | −5,133 | −$210.15K |
| 2026-09-14 | Epperly Melissa B, | Director | F | −2,179 | −$89.21K |
| 2026-09-10 | Meghan Fitzgerald | Director | MIXED | — | −$622.00K |
| 2026-09-01 | Eric Venker | President & Immunovant CEO | MIXED | — | −$6.38M |
| 2026-08-24 | Eric Venker | President & Immunovant CEO | F | −13,909 | −$512.41K |
| 2026-08-24 | Richard Pulik | CFO | F | −5,749 | −$211.79K |
| 2026-08-21 | Mayukh Sukhatme | President & CIO | MIXED | — | −$11.07M |
| 2026-08-18 | Mayukh Sukhatme | President & CIO | MIXED | — | −$21.60M |
| 2026-07-29 | Eric Venker | President & Immunovant CEO | MIXED | — | −$6.22M |
| 2026-07-21 | James C Momtazee | Director | A | +405 | — |
| 2026-07-21 | Ilan Oren | Director | A | +775 | — |
| 2026-07-21 | Epperly Melissa B, | Director | A | +543 | — |
| 2026-07-02 | Matthew Gline | CEO | F | −76,171 | −$2.70M |
| 2026-07-02 | Frank Torti | President and Vant Chair | F | −40,310 | −$1.43M |
| 2026-07-02 | Mayukh Sukhatme | President & CIO | F | −46,878 | −$1.66M |
| 2026-07-02 | Meghan Fitzgerald | Director | MIXED | — | −$261.00K |
| 2026-07-01 | Epperly Melissa B, | Director | MIXED | — | −$531.09K |
| 2026-06-29 | Mayukh Sukhatme | President & CIO | MIXED | — | −$30.25M |
| 2026-06-26 | Eric Venker | President & Immunovant CEO | MIXED | — | −$5.86M |
| 2026-06-23 | Richard Pulik | CFO | F | −2,129 | −$66.91K |
| 2026-06-23 | Jennifer Humes | Chief Accounting Officer | F | −3,582 | −$112.58K |
| 2026-05-22 | Richard Pulik | CFO | F | −18,962 | −$614.56K |
| 2026-05-22 | Eric Venker | President & Immunovant CEO | MIXED | −34,483 | −$6.40M |
| 2026-04-22 | Jennifer Humes | Chief Accounting Officer | A | +29,173 | — |
| 2026-04-22 | Richard Pulik | CFO | A | +60,644 | — |
| 2026-04-22 | Eric Venker | President & Immunovant CEO | MIXED | — | −$5.15M |
| 2026-04-21 | James C Momtazee | Director | MIXED | +375 | −$2.80K |
| 2026-04-21 | Epperly Melissa B, | Director | A | +670 | — |
| 2026-04-21 | Ilan Oren | Director | MIXED | +801 | −$2.83K |
| 2026-04-20 | Matthew Gline | CEO | Sell | −289,774 | −$8.45M |
| 2026-04-10 | Jennifer Humes | Chief Accounting Officer | Sell | −13,538 | −$384.07K |
| 2026-04-02 | Frank Torti | President and Vant Chair | F | −160,035 | −$4.43M |
| 2026-04-01 | Mayukh Sukhatme | President & CIO | MIXED | −158,930 | −$5.98M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Vivek Ramaswamy | 10%+ Owner | 47,011,612 | $1.69B |
| Daniel Allen Gold | Director | 24,468,928 | $879.66M |
| Mayukh Sukhatme | President & CIO | 20,241,558 | $727.68M |
| Keith S Manchester | Director | 16,880,786 | $606.86M |
| Matthew Gline | CEO | 16,583,774 | $596.19M |
| QVT Financial LP | — | 15,928,113 | $572.62M |
| Frank Torti | President and Vant Chair | 13,495,893 | $485.18M |
| Eric Venker | President & Immunovant CEO | 1,599,154 | $57.49M |
| Richard Pulik | CFO | 269,681 | $9.70M |
| Rakhi Kumar | Chief Accounting Officer | 162,306 | $5.83M |
| Ilan Oren | Director | 123,680 | $4.45M |
| James C Momtazee | Director | 111,959 | $4.02M |
| Jennifer Humes | Chief Accounting Officer | 106,419 | $3.83M |
| Meghan Fitzgerald | Director | 41,162 | $1.48M |
| Epperly Melissa B, | Director | 14,954 | $537.60K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ROIV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.